Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Hymenoptera Venom Allergy and Anaphylaxis

Author(s): Maria Beatrice Bilò*, Maria Giovanna Danieli, Gianluca Moroncini and Matteo Martini*

Volume 29, Issue 3, 2023

Published on: 27 August, 2022

Page: [165 - 177] Pages: 13

DOI: 10.2174/1381612828666220817091039

Price: $65

Abstract

Hymenoptera stings can induce allergic and occasionally fatal reactions, and are responsible for significant morbidity and deterioration in health-related quality of life. The diagnostic work-up must consider the medical history of patients, in the context of venom allergy epidemiology and Hymenoptera taxonomy, and the clinical manifestations of the reactions, to channel the available in vivo and in vitro tests towards the most accurate diagnosis and the consequent appropriate management, also considering the risk profile of the patients on a precision-medicine approach. All these aspects are covered by this work that aims at providing an up-to-date review to increase the awareness of this topic among interested stakeholders, like healthcare professionals and political decision makers, who can contribute to the proper immediate and long-term management of venom allergy and anaphylaxis.

Keywords: Anaphylaxis, hymenoptera taxonomy, health-related quality of life, cardiovascular, hymenoptera venom allergy, systemic reactions.

« Previous Next »
[1]
Biló BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN. Diagnosis of hymenoptera venom allergy. Allergy 2005; 60(11): 1339-49.
[http://dx.doi.org/10.1111/j.1398-9995.2005.00963.x] [PMID: 16197464]
[2]
Krishna MT, Ewan PW, Diwakar L, et al. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin Exp Allergy 2011; 41(9): 1201-20.
[http://dx.doi.org/10.1111/j.1365-2222.2011.03788.x] [PMID: 21848758]
[3]
Golden DBKK, Demain J, Freeman T, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol 2017; 118(1): 28-54.
[http://dx.doi.org/10.1016/j.anai.2016.10.031] [PMID: 28007086]
[4]
Simons FER, Ardusso LRF, Bilò MB, et al. World allergy organization anaphylaxis guidelines: Summary. J Allergy Clin Immunol 2011; 127(3): 587-93.e1, 22.
[http://dx.doi.org/10.1016/j.jaci.2011.01.038] [PMID: 21377030]
[5]
Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 2020; 13(10): 100472.
[http://dx.doi.org/10.1016/j.waojou.2020.100472] [PMID: 33204386]
[6]
Abrams EM, Golden DBK. Approach to patients with stinging insect allergy. Med Clin North Am 2020; 104(1): 129-43.
[http://dx.doi.org/10.1016/j.mcna.2019.08.006] [PMID: 31757231]
[7]
Muraro A, Worm M, Alviani C, et al. EAACI guideline: Anaphylaxis (2021 update). Allergy 2022; 77(2): 357-77.
[http://dx.doi.org/10.1111/all.15032] [PMID: 34343358]
[8]
Golden DBK. Insect sting anaphylaxis. Immunol Allergy Clin North Am 2007; 27(2): 261-72.
[http://dx.doi.org/10.1016/j.iac.2007.03.008] [PMID: 17493502]
[9]
Simons FER. Anaphylaxis. J Allergy Clin Immunol 2010; 125(2) (Suppl. 2): S161-81.
[http://dx.doi.org/10.1016/j.jaci.2009.12.981] [PMID: 20176258]
[10]
Lockey RF, Turkeltaub PC, Baird-Warren IA, et al. The Hymenoptera venom study I, 1979-1982: Demographics and historysting data. J Allergy Clin Immunol 1988; 82(3 Pt 1): 370-81.
[http://dx.doi.org/10.1016/0091-6749(88)90008-5] [PMID: 3170986]
[11]
Bilò MB, Pravettoni V, Bignardi D, et al. Hymenoptera venom allergy: Management of children and adults in clinical practice. J Investig Allergol Clin Immunol 2019; 29(3): 180-205.
[http://dx.doi.org/10.18176/jiaci.0310] [PMID: 30183660]
[12]
Dodd A, Hughes A, Sargant N, Whyte AF, Soar J, Turner PJ. Evidence update for the treatment of anaphylaxis. Resuscitation 2021; 163: 86-96.
[http://dx.doi.org/10.1016/j.resuscitation.2021.04.010] [PMID: 33895231]
[13]
Lee S, Sadosty AT, Campbell RL. Update on biphasic anaphylaxis. Curr Opin Allergy Clin Immunol 2016; 16(4): 346-51.
[http://dx.doi.org/10.1097/ACI.0000000000000279] [PMID: 27253484]
[14]
Francuzik W, Ruëff F, Bauer A, et al. Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European anaphylaxis registry. J Allergy Clin Immunol 2021; 147(2): 653-662.e9.
[http://dx.doi.org/10.1016/j.jaci.2020.06.008] [PMID: 32585173]
[15]
Kounis NG. Kounis syndrome: An update on epidemiology, pathogenesis, diagnosis and therapeutic management. Clin Chem Lab Med 2016; 54(10): 1545-59.
[http://dx.doi.org/10.1515/cclm-2016-0010] [PMID: 26966931]
[16]
Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: Cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012; 130(3): 698-704.e1.
[http://dx.doi.org/10.1016/j.jaci.2012.03.024] [PMID: 22554708]
[17]
Lyons JJ, Chovanec J, O’Connell MP, et al. Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol 2021; 147(2): 622-32.
[http://dx.doi.org/10.1016/j.jaci.2020.06.035] [PMID: 32717252]
[18]
Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123(3): 680-6.
[http://dx.doi.org/10.1016/j.jaci.2008.11.018] [PMID: 19135713]
[19]
Demain JG, Gessner BD, McLaughlin JB, Sikes DS, Foote JT. Increasing insect reactions in Alaska: Is this related to changing climate? Allergy Asthma Proc 2009; 30(3): 238-43.
[http://dx.doi.org/10.2500/aap.2009.30.3231] [PMID: 19549424]
[20]
Golden DBK. Update on insect sting anaphylaxis. Curr Allergy Asthma Rep 2021; 21(3): 16.
[http://dx.doi.org/10.1007/s11882-021-00998-w] [PMID: 33666774]
[21]
Bilò MB, Martini M, Pravettoni V, et al. Large local reactions to Hymenoptera stings: Outcome of re‐stings in real life. Allergy 2019; 74(10): 1969-76.
[22]
Bilò BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8(4): 330-7.
[http://dx.doi.org/10.1097/ACI.0b013e32830638c5] [PMID: 18596590]
[23]
Bilò MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: Clinical implications. Clin Exp Allergy 2009; 39(10): 1467-76.
[http://dx.doi.org/10.1111/j.1365-2222.2009.03324.x] [PMID: 19622088]
[24]
Bilò MB. Anaphylaxis caused by Hymenoptera stings: From epidemiology to treatment. Allergy 2011; 66 (Suppl. 95): 35-7.
[http://dx.doi.org/10.1111/j.1398-9995.2011.02630.x] [PMID: 21668850]
[25]
Severino M, Bonadonna P, Passalacqua G. Large local reactions from stinging insects: From epidemiology to management. Curr Opin Allergy Clin Immunol 2009; 9(4): 334-7.
[http://dx.doi.org/10.1097/ACI.0b013e32832d0668] [PMID: 19458526]
[26]
Graft DF, Schuberth KC, Kagey-Sobotka A, et al. A prospective study of the natural history of large local reactions after Hymenoptera stings in children. J Pediatr 1984; 104(5): 664-8.
[http://dx.doi.org/10.1016/S0022-3476(84)80940-3] [PMID: 6716215]
[27]
Mauriello PM, Barde SH, Georgitis JW, Reisman RE. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 1984; 74(4 Pt 1): 494-8.
[http://dx.doi.org/10.1016/0091-6749(84)90384-1] [PMID: 6491095]
[28]
Golden DBK, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004; 351(7): 668-74.
[http://dx.doi.org/10.1056/NEJMoa022952] [PMID: 15306668]
[29]
Golden DBK, Breisch NL, Hamilton RG, et al. Clinical and entomological factors influence the outcome of sting challenge studies. J Allergy Clin Immunol 2006; 117(3): 670-5.
[http://dx.doi.org/10.1016/j.jaci.2005.12.1313] [PMID: 16522469]
[30]
Pucci S, D’Alò S, De Pasquale T, Illuminati I, Makri E, Incorvaia C. Risk of anaphylaxis in patients with large local reactions to hymenoptera stings: A retrospective and prospective study. Clin Mol Allergy 2015; 13: 21.
[http://dx.doi.org/10.1186/s12948-015-0030-z] [PMID: 26557045]
[31]
Worm M, Moneret-Vautrin A, Scherer K, et al. First European data from the network of severe allergic reactions (NORA). Allergy 2014; 69(10): 1397-404.
[http://dx.doi.org/10.1111/all.12475] [PMID: 24989080]
[32]
Minale P, Bignardi D, Troise C, Voltolini S, Dignetti P. A regional approach to unmet needs in anaphylaxis. Eur Ann Allergy Clin Immunol 2016; 48(3): 88-93.
[PMID: 27152604]
[33]
Bilò MB, Corsi A, Martini M, Penza E, Grippo F, Bignardi D. Fatal anaphylaxis in Italy: Analysis of cause-of-death national data, 2004-2016. Allergy 2020; 75(10): 2644-52.
[http://dx.doi.org/10.1111/all.14352] [PMID: 32364284]
[34]
Mosbech H. Death caused by wasp and bee stings in Denmark 1960-1980. Allergy 1983; 38(3): 195-200.
[http://dx.doi.org/10.1111/j.1398-9995.1983.tb01606.x] [PMID: 6846747]
[35]
Golden DBK. Insect sting allergy and venom immunotherapy: A model and a mystery. J Allergy Clin Immunol 2005; 115(3): 439-47.
[http://dx.doi.org/10.1016/j.jaci.2005.01.005] [PMID: 15753884]
[36]
Pucci S, Antonicelli L, Bilò MB, Garritani MS, Bonifazi F. Shortness of interval between two stings as risk factor for developing Hymenoptera venom allergy. Allergy 1994; 49(10): 894-6.
[http://dx.doi.org/10.1111/j.1398-9995.1994.tb00796.x] [PMID: 7710003]
[37]
Pravettoni V, Piantanida M, Primavesi L, Forti S, Pastorello EA. Basal platelet-activating factor acetylhydrolase: Prognostic marker of severe Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2014; 133(4): 1218-20.
[http://dx.doi.org/10.1016/j.jaci.2013.10.033] [PMID: 24332861]
[38]
Worm M, Francuzik W, Renaudin J-M, et al. Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry. Allergy 2018; 73(6): 1322-30.
[http://dx.doi.org/10.1111/all.13380] [PMID: 29318637]
[39]
Ruëff F, Przybilla B, Biló MB, et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: The importance of baseline serum tryptase. J Allergy Clin Immunol 2010; 126(1): 105-11.e5.
[http://dx.doi.org/10.1016/j.jaci.2010.04.025] [PMID: 20542320]
[40]
Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: Temporal patterns and demographic associations. J Allergy Clin Immunol 2014; 134(6): 1318-1328.e7.
[http://dx.doi.org/10.1016/j.jaci.2014.08.018] [PMID: 25280385]
[41]
Ruëff F. Natural history and long-term follow-up of Hymenoptera allergy. Curr Opin Allergy Clin Immunol 2020; 20(5): 445-51.
[http://dx.doi.org/10.1097/ACI.0000000000000671] [PMID: 32739977]
[42]
Worm M, Edenharter G, Ruëff F, et al. Symptom profile and risk factors of anaphylaxis in Central Europe. Allergy 2012; 67(5): 691-8.
[http://dx.doi.org/10.1111/j.1398-9995.2012.02795.x] [PMID: 22335765]
[43]
Ludolph-Hauser D, Ruëff F, Fries C, Schöpf P, Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357(9253): 361-2.
[http://dx.doi.org/10.1016/S0140-6736(00)03647-3] [PMID: 11211002]
[44]
Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: Importance of baseline serum tryptase-a study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. J Allergy Clin Immunol 2009; 124(5): 1047-54.
[http://dx.doi.org/10.1016/j.jaci.2009.08.027] [PMID: 19895993]
[45]
Yavuz ST, Sahiner UM, Buyuktiryaki B, et al. Clinical features of children with venom allergy and risk factors for severe systemic reactions. Int Arch Allergy Immunol 2013; 160(3): 313-21.
[http://dx.doi.org/10.1159/000341666] [PMID: 23095437]
[46]
Blank S, Grosch J, Ollert M, Bilò MB. Precision medicine in hymenoptera venom allergy: Diagnostics, biomarkers, and therapy of different endotypes and phenotypes. Front Immunol 2020; 11: 579409.
[http://dx.doi.org/10.3389/fimmu.2020.579409] [PMID: 33193378]
[47]
Sturm GJ, Herzog SA, Aberer W, et al. β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy. Allergy 2021; 76(7): 2166-76.
[http://dx.doi.org/10.1111/all.14785] [PMID: 33605465]
[48]
Antonicelli L, Bilò MB, Napoli G, Farabollini B, Bonifazi F. European hornet (Vespa crabro) sting: A new risk factor for life-threatening reaction in hymenoptera allergic patients? Eur Ann Allergy Clin Immunol 2003; 35(6): 199-203.
[PMID: 12872677]
[49]
Hayashi Y, Hirata H, Watanabe M, et al. Epidemiologic investigation of hornet and paper wasp stings in forest workers and electrical facility field workers in Japan. Allergol Int 2014; 63(1): 21-6.
[http://dx.doi.org/10.2332/allergolint.13-OA-0556] [PMID: 24270224]
[50]
Ricciardi L, Papia F, Cataldo G, Giorgianni M, Spatari G, Gangemi S. Hymenoptera sting reactions in southern Italy forestry workers: Our experience compared to reported data. Clin Mol Allergy 2018; 16: 8.
[http://dx.doi.org/10.1186/s12948-018-0087-6] [PMID: 29686538]
[51]
Soriano-Gomis V, Cabrera-Beyrouti R, Serrano-Delgado P, Jimenez-Rodriguez TW, Gómez MB, Fernandez-Sanchez J. Epidemiology of hymenoptera venom allergy in the Valencia Fire Brigade (Spain). J Allergy Clin Immunol Pract 2021; 9(2): 1037-1038.e2.
[http://dx.doi.org/10.1016/j.jaip.2020.09.038] [PMID: 33038590]
[52]
Zink A, Schuster B, Winkler J, et al. Allergy and sensitization to hymenoptera venoms in unreferred adults with a high risk of sting exposure. World Allergy Organ J 2019; 12(7): 100039.
[http://dx.doi.org/10.1016/j.waojou.2019.100039] [PMID: 31312341]
[53]
Siracusa A, Folletti I, Gerth van Wijk R, et al. Occupational anaphylaxis--an EAACI task force consensus statement. Allergy 2015; 70(2): 141-52.
[http://dx.doi.org/10.1111/all.12541] [PMID: 25369880]
[54]
Grosch J, Hilger C, Bilò MB, et al. Shedding light on the venom proteomes of the allergy-relevant hymenoptera Polistes dominula (European paper wasp) and Vespula spp. (yellow jacket). Toxins 2020; 12(5): E323.
[http://dx.doi.org/10.3390/toxins12050323] [PMID: 32422898]
[55]
Grosch J, Eberlein B, Waldherr S, et al. Characterization of new allergens from the venom of the European paper wasp Polistes dominula. Toxins (Basel) 2021; 13(8): 559.
[http://dx.doi.org/10.3390/toxins13080559] [PMID: 34437431]
[56]
Blank S, Bazon ML, Grosch J, et al. Antigen 5 allergens of hymenoptera venoms and their role in diagnosis and therapy of venom allergy. Curr Allergy Asthma Rep 2020; 20(10): 58.
[http://dx.doi.org/10.1007/s11882-020-00954-0] [PMID: 32647993]
[57]
Blank S, Seismann H, Bockisch B, et al. Identification, recombinant expression, and characterization of the 100 kDa high molecular weight hymenoptera venom allergens Api m 5 and Ves v 3. J Immunol 2010; 184(9): 5403-13.
[http://dx.doi.org/10.4049/jimmunol.0803709] [PMID: 20348419]
[58]
Hoffman DR, Sakell RH, Schmidt M. Sol i 1, the phospholipase allergen of imported fire ant venom. J Allergy Clin Immunol 2005; 115(3): 611-6.
[http://dx.doi.org/10.1016/j.jaci.2004.11.020] [PMID: 15753912]
[59]
Monsalve RI, Vega A, Marqués L, et al. Component-resolved diagnosis of vespid venom-allergic individuals: Phospholipases and antigen 5s are necessary to identify Vespula or Polistes sensitization. Allergy 2012; 67(4): 528-36.
[http://dx.doi.org/10.1111/j.1398-9995.2011.02781.x] [PMID: 22229815]
[60]
Schiener M, Eberlein B, Moreno-Aguilar C, et al. Application of recombinant antigen 5 allergens from seven allergy-relevant Hymenoptera species in diagnostics. Allergy 2017; 72(1): 98-108.
[http://dx.doi.org/10.1111/all.13000] [PMID: 27496543]
[61]
Jin C, Focke M, Léonard R, Jarisch R, Altmann F, Hemmer W. Reassessing the role of hyaluronidase in yellow jacket venom allergy. J Allergy Clin Immunol 2010; 125(1): 184-90.e1.
[http://dx.doi.org/10.1016/j.jaci.2009.08.037] [PMID: 19910026]
[62]
Schiener M, Hilger C, Eberlein B, et al. The high molecular weight dipeptidyl peptidase IV Pol d 3 is a major allergen of Polistes dominula venom. Sci Rep 2018; 8(1): 1318.
[http://dx.doi.org/10.1038/s41598-018-19666-7] [PMID: 29358620]
[63]
Blank S, Seismann H, McIntyre M, et al. Vitellogenins are new high molecular weight components and allergens (Api m 12 and Ves v 6) of Apis mellifera and Vespula vulgaris venom. PLoS One 2013; 8(4): e62009-9.
[http://dx.doi.org/10.1371/journal.pone.0062009] [PMID: 23626765]
[64]
Frick M, Müller S, Bantleon F, et al. rApi m 3 and rApi m 10 improve detection of honey bee sensitization in hymenoptera venom-allergic patients with double sensitization to honey bee and yellow jacket venom. Allergy 2015; 70(12): 1665-8.
[http://dx.doi.org/10.1111/all.12725] [PMID: 26259841]
[65]
Ruiz B, Serrano P, Moreno C. IgE-Api m 4 is useful for identifying a particular phenotype of bee venom allergy. J Investig Allergol Clin Immunol 2016; 26(6): 355-61.
[http://dx.doi.org/10.18176/jiaci.0053] [PMID: 27996941]
[66]
Frick M, Fischer J, Helbling A, et al. Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy. J Allergy Clin Immunol 2016; 138(6): 1663-1671.e9.
[http://dx.doi.org/10.1016/j.jaci.2016.04.024] [PMID: 27372568]
[67]
Severino MG, Campi P, Macchia D, et al. European Polistes venom allergy. Allergy 2006; 61(7): 860-3.
[http://dx.doi.org/10.1111/j.1398-9995.2006.01077.x] [PMID: 16792585]
[68]
González-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy 2011; 3(5): 637-51.
[http://dx.doi.org/10.2217/imt.11.44] [PMID: 21554093]
[69]
Vos B, Köhler J, Müller S, Stretz E, Ruëff F, Jakob T. Spiking venom with rVes v 5 improves sensitivity of IgE detection in patients with allergy to Vespula venom. J Allergy Clin Immunol 2013; 131(4): 1225-1227, 1227.e1.
[http://dx.doi.org/10.1016/j.jaci.2012.07.041] [PMID: 23006544]
[70]
Blank S, Seismann H, Michel Y, et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy 2011; 66(10): 1322-9.
[http://dx.doi.org/10.1111/j.1398-9995.2011.02667.x] [PMID: 21658068]
[71]
Alvarez-Twose I, González-de-Olano D, Sánchez-Muñoz L, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol 2012; 157(3): 275-80.
[http://dx.doi.org/10.1159/000329856] [PMID: 22042301]
[72]
Bilò MB, Ollert M, Blank S. The role of component-resolved diagnosis in hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2019; 19(6): 614-22.
[http://dx.doi.org/10.1097/ACI.0000000000000574] [PMID: 31343438]
[73]
Jakob T, Müller U, Helbling A, Spillner E. Component resolved diagnostics for hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2017; 17(5): 363-72.
[http://dx.doi.org/10.1097/ACI.0000000000000390] [PMID: 28759475]
[74]
Blank S, Bilò MB, Ollert M. Component-resolved diagnostics to direct in venom immunotherapy: Important steps towards precision medicine. Clin Exp Allergy 2018; 48(4): 354-64.
[http://dx.doi.org/10.1111/cea.13090] [PMID: 29331065]
[75]
Ebo DG, Faber M, Sabato V, Leysen J, Bridts CH, De Clerck LS. Component-resolved diagnosis of wasp (yellow jacket) venom allergy. Clin Exp Allergy 2013; 43(2): 255-61.
[http://dx.doi.org/10.1111/cea.12057] [PMID: 23331567]
[76]
Bilò MB, Martini M, Bonadonna P, et al. Prevalence of Pol d 1 sensitization in polistes dominula allergy and its diagnostic role in vespid double-positivity. J Allergy Clin Immunol Pract 2021; 9(10): 3781-7.
[http://dx.doi.org/10.1016/j.jaip.2021.05.033] [PMID: 34146747]
[77]
Caruso B, Bonadonna P, Severino MG, et al. Evaluation of the IgE cross-reactions among vespid venoms. A possible approach for the choice of immunotherapy. Allergy 2007; 62(5): 561-4.
[http://dx.doi.org/10.1111/j.1398-9995.2007.01353.x] [PMID: 17441797]
[78]
Savi E, Peveri S, Makri E, Pravettoni V, Incorvaia C. Comparing the ability of molecular diagnosis and CAP-inhibition in identifying the really causative venom in patients with positive tests to Vespula and Polistes species. Clin Mol Allergy 2016; 14: 3.
[http://dx.doi.org/10.1186/s12948-016-0040-5] [PMID: 26858583]
[79]
Quercia O, Cova V, Martini M, et al. CAP-inhibition, molecular diagnostics, and total IgE in the evaluation of polistes and vespula double sensitization. Int Arch Allergy Immunol 2018; 177(4): 365-9.
[http://dx.doi.org/10.1159/000491939] [PMID: 30176659]
[80]
Caruso B, Bonadonna P, Bovo C, et al. Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to Vespula and Polistes subspecies. Clin Chim Acta 2016; 453: 170-3.
[http://dx.doi.org/10.1016/j.cca.2015.12.026] [PMID: 26719033]
[81]
Eberlein B, Krischan L, Darsow U, Ollert M, Ring J. Double positivity to bee and wasp venom: Improved diagnostic procedure by recombinant allergen-based IgE testing and basophil activation test including data about cross-reactive carbohydrate determinants. J Allergy Clin Immunol 2012; 130(1): 155-61.
[http://dx.doi.org/10.1016/j.jaci.2012.02.008] [PMID: 22421265]
[82]
Korosec P, Erzen R, Silar M, Bajrovic N, Kopac P, Kosnik M. Basophil responsiveness in patients with insect sting allergies and negative venom-specific immunoglobulin E and skin prick test results. Clin Exp Allergy 2009; 39(11): 1730-7.
[http://dx.doi.org/10.1111/j.1365-2222.2009.03347.x] [PMID: 19689457]
[83]
Sturm GJ, Jin C, Kranzelbinder B, et al. Inconsistent results of diagnostic tools hamper the differentiation between bee and vespid venom allergy. PLoS One 2011; 6(6): e20842.
[http://dx.doi.org/10.1371/journal.pone.0020842] [PMID: 21698247]
[84]
Bokanovic D, Arzt-Gradwohl L, Schwarz I, et al. Possible utility of basophil activation test in dual honeybee and vespid sensitization. J Allergy Clin Immunol Pract 2020; 8(1): 392-394.e5.
[http://dx.doi.org/10.1016/j.jaip.2019.06.008] [PMID: 31233939]
[85]
Bonadonna P, Zanotti R, Melioli G, et al. The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. Allergy 2012; 67(7): 962-5.
[http://dx.doi.org/10.1111/j.1398-9995.2012.02849.x] [PMID: 22676063]
[86]
Rietveld MJA, Schreurs MWJ, Gerth van Wijk R, van Daele PL, Hermans MA. The basophil activation test is not a useful screening tool for hymenoptera venom-related anaphylaxis in patients with systemic mastocytosis. Int Arch Allergy Immunol 2016; 169(2): 125-9.
[http://dx.doi.org/10.1159/000444996] [PMID: 27055231]
[87]
Aßmus K, Meissner M, Kaufmann R, Valesky EM. Benefits and limitations of sting challenge in hymenoptera venom allergy. Allergol Select 2021; 5: 45-50.
[http://dx.doi.org/10.5414/ALX02148E] [PMID: 33490858]
[88]
Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145(4): 1082-123.
[http://dx.doi.org/10.1016/j.jaci.2020.01.017] [PMID: 32001253]
[89]
Bilò MB, Cichocka-Jarosz E, Pumphrey R, et al. Self-medication of anaphylactic reactions due to hymenoptera stings-an EAACI task force consensus statement. Allergy 2016; 71(7): 931-43.
[http://dx.doi.org/10.1111/all.12908]
[90]
Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller U. Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice. Allergy 2005; 60(12): 1459-70.
[http://dx.doi.org/10.1111/j.1398-9995.2005.00960.x] [PMID: 16266376]
[91]
Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2018; 73(4): 744-64.
[http://dx.doi.org/10.1111/all.13262] [PMID: 28748641]
[92]
Bonadonna P, Gonzalez-de-Olano D, Zanotti R, et al. Venom immunotherapy in patients with clonal mast cell disorders: Efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract 2013; 1(5): 474-8.
[http://dx.doi.org/10.1016/j.jaip.2013.06.014] [PMID: 24565619]
[93]
Oude Elberink JNG, De Monchy JGR, Van Der Heide S, Guyatt GH, Dubois AE. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002; 110(1): 174-82.
[http://dx.doi.org/10.1067/mai.2002.125827] [PMID: 12110838]
[94]
Oude Elberink JNG, van der Heide S, Guyatt GH, Dubois AE. Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis. J Allergy Clin Immunol 2006; 118(3): 699-704.
[http://dx.doi.org/10.1016/j.jaci.2006.03.049] [PMID: 16950290]
[95]
Bilò MB, Kamberi E, Tontini C, et al. High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: A real-life experience. J Allergy Clin Immunol Pract 2016; 4(2): 327-9.e1.
[http://dx.doi.org/10.1016/j.jaip.2015.09.014] [PMID: 26563675]
[96]
Aeberhard J, Haeberli G, Müller UR, Helbling A. Specific immunotherapy in hymenoptera venom allergy and concomitant malignancy: A retrospective follow-up focusing on effectiveness and safety. J Investig Allergol Clin Immunol 2017; 27(6): 370-7.
[http://dx.doi.org/10.18176/jiaci.0184] [PMID: 28675375]
[97]
Pitsios C, Demoly P, Bilò MB, et al. Clinical contraindications to allergen immunotherapy: An EAACI position paper. Allergy 2015; 70(8): 897-909.
[http://dx.doi.org/10.1111/all.12638] [PMID: 25913519]
[98]
Ruëff F, Vos B, Oude Elberink J, et al. Predictors of clinical effectiveness of hymenoptera venom immunotherapy. Clin Exp Allergy 2014; 44(5): 736-46.
[http://dx.doi.org/10.1111/cea.12275] [PMID: 24447114]
[99]
Köhler J, Blank S, Müller S, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. J Allergy Clin Immunol 2014; 133: 1383-9.
[http://dx.doi.org/10.1016/j.jaci.2013.10.060]
[100]
Müller UR. Bee venom allergy in beekeepers and their family members. Curr Opin Allergy Clin Immunol 2005; 5(4): 343-7.
[http://dx.doi.org/10.1097/01.all.0000173783.42906.95] [PMID: 15985817]
[101]
de Groot H. Allergy to bumblebees. Curr Opin Allergy Clin Immunol 2006; 6(4): 294-7.
[http://dx.doi.org/10.1097/01.all.0000235905.87676.09] [PMID: 16825872]
[102]
Goldberg A, Confino-Cohen R. Bee venom immunotherapy - how early is it effective? Allergy 2010; 65(3): 391-5.
[http://dx.doi.org/10.1111/j.1398-9995.2009.02198.x] [PMID: 19839973]
[103]
Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN. Mastocytosis and insect venom allergy: Diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64(9): 1237-45.
[http://dx.doi.org/10.1111/j.1398-9995.2009.02118.x] [PMID: 19627278]
[104]
Houliston L, Nolan R, Noble V, et al. Honeybee venom immunotherapy in children using a 50-μg maintenance dose. J Allergy Clin Immunol 2011; 127(1): 98-9.
[http://dx.doi.org/10.1016/j.jaci.2010.07.031] [PMID: 20864150]
[105]
Konstantinou GN, Manoussakis E, Douladiris N, et al. A 5-year venom immunotherapy protocol with 50 μg maintenance dose: Safety and efficacy in school children. Pediatr Allergy Immunol 2011; 22(4): 393-7.
[http://dx.doi.org/10.1111/j.1399-3038.2010.01137.x] [PMID: 21235631]
[106]
Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108(6): 1027-32.
[http://dx.doi.org/10.1067/mai.2001.119154] [PMID: 11742283]
[107]
Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: Extended observations. J Allergy Clin Immunol 1998; 101(3): 298-305.
[http://dx.doi.org/10.1016/S0091-6749(98)70239-8] [PMID: 9525443]
[108]
Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients. J Allergy Clin Immunol 1998; 101(5): 606-12.
[http://dx.doi.org/10.1016/S0091-6749(98)70167-8] [PMID: 9600496]
[109]
Reisman RE. Duration of venom immunotherapy: Relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993; 92(6): 831-6.
[http://dx.doi.org/10.1016/0091-6749(93)90060-S] [PMID: 8258617]
[110]
Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000; 105(2 Pt 1): 385-90.
[http://dx.doi.org/10.1016/S0091-6749(00)90092-7] [PMID: 10669863]
[111]
Martini M, Corsi A, Agolini S, Marchionni A, Antonicelli L, Bilò MB. High long-term efficacy of venom immunotherapy after discontinuation. Allergy 2020; 75(7): 1793-6.
[http://dx.doi.org/10.1111/all.14224] [PMID: 32043579]
[112]
Bonadonna P, Zanotti R, Pagani M, et al. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: A clonal mast cell disorder should be suspected. J Allergy Clin Immunol Pract 2018; 6(4): 1368-72.
[http://dx.doi.org/10.1016/j.jaip.2017.11.025] [PMID: 29258788]

Rights & Permissions Print Cite
Article Metrics
44
2
World Chronic Fatigue Syndrome Awareness Day
© 2024 Bentham Science Publishers | Privacy Policy